Related Experiment Video
Updated: Jul 4, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
Named Entity Recognition and Normalization for Alzheimer's Disease Eligibility Criteria
1School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas.
None:
Alzheimer's Disease (AD) is a complex neurodegenerative disorder that affects millions of people worldwide. Finding effective treatments for this disease is crucial. Clinical trials play an essential role in developing and testing new treatments for AD. However, identifying eligible participants can be challenging, time-consuming, and costly. In recent years, the development of natural language processing (NLP) techniques, specifically named entity recognition (NER) and named entity normalization (NEN), have helped to automate the identification and extraction of relevant information from the eligibility criteria (EC) more efficiently, in order to facilitate semi-automatic patient recruitment and enable data FAIRness for clinical trial data. Nevertheless, most current biomedical NER models only provide annotations for a restricted set of entity types that may not be applicable to the clinical trial data. Additionally, accurately performing NEN on entities that are negated using a negative prefix currently lacks established techniques. In this paper, we introduce a pipeline designed for information extraction from AD clinical trial EC, which involves preprocessing of the EC data, clinical NER, and biomedical NEN to Unified Medical Language System (UMLS). Our NER model can identify named entities in seven pre-defined categories, while our NEN model employs a combination of exact match and partial match search strategies, as well as customized rules to accurately normalize entities with negative prefixes. To evaluate the performance of our pipeline, we measured the precision, recall, and F1 score for the NER component, and we manually reviewed the top five mapping results produced by the NEN component. Our evaluation of the pipeline's performance revealed that it can successfully normalize named entities in clinical trial ECs with optimal accuracies. The NER component achieved a overall F1 of 0.816, demonstrating its ability to accurately identify seven types of named entities in clinical text. The NEN component of the pipeline also demonstrated impressive performance, with customized rules and a combination of exact and partial match strategies leading to an accuracy of 0.940 for normalized entities.
More Related Videos
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Neural Regulation
Prosopagnosia